JP2018535921A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535921A5 JP2018535921A5 JP2018507002A JP2018507002A JP2018535921A5 JP 2018535921 A5 JP2018535921 A5 JP 2018535921A5 JP 2018507002 A JP2018507002 A JP 2018507002A JP 2018507002 A JP2018507002 A JP 2018507002A JP 2018535921 A5 JP2018535921 A5 JP 2018535921A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- molecule
- disease
- tau
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000013498 tau Proteins Human genes 0.000 claims description 30
- 108010026424 tau Proteins Proteins 0.000 claims description 30
- 150000001413 amino acids Chemical group 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 11
- 208000024827 Alzheimer disease Diseases 0.000 claims description 9
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 9
- 206010012289 Dementia Diseases 0.000 claims description 8
- 210000004556 brain Anatomy 0.000 claims description 8
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 6
- 206010034010 Parkinsonism Diseases 0.000 claims description 6
- 230000005856 abnormality Effects 0.000 claims description 6
- 208000017004 dementia pugilistica Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 5
- 238000005259 measurement Methods 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 4
- 102100034452 Alternative prion protein Human genes 0.000 claims description 3
- 206010059245 Angiopathy Diseases 0.000 claims description 3
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims description 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 3
- 208000009093 Diffuse Neurofibrillary Tangles with Calcification Diseases 0.000 claims description 3
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- 206010018341 Gliosis Diseases 0.000 claims description 3
- 208000026072 Motor neurone disease Diseases 0.000 claims description 3
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 3
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 3
- 208000010577 Niemann-Pick disease type C Diseases 0.000 claims description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 3
- 108091000054 Prion Proteins 0.000 claims description 3
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 210000004227 basal ganglia Anatomy 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 210000000349 chromosome Anatomy 0.000 claims description 3
- 230000001054 cortical effect Effects 0.000 claims description 3
- 230000007850 degeneration Effects 0.000 claims description 3
- 230000007387 gliosis Effects 0.000 claims description 3
- 201000008319 inclusion body myositis Diseases 0.000 claims description 3
- 208000005264 motor neuron disease Diseases 0.000 claims description 3
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 230000002739 subcortical effect Effects 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 2
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 claims description 2
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 claims description 2
- 208000034189 Sclerosis Diseases 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 229950006137 dexfosfoserine Drugs 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 230000005298 paramagnetic effect Effects 0.000 claims description 2
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims description 2
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 210000001779 taste bud Anatomy 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 208000029028 brain injury Diseases 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000011503 in vivo imaging Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562204711P | 2015-08-13 | 2015-08-13 | |
| US62/204,711 | 2015-08-13 | ||
| PCT/US2016/046520 WO2017027691A1 (en) | 2015-08-13 | 2016-08-11 | Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018535921A JP2018535921A (ja) | 2018-12-06 |
| JP2018535921A5 true JP2018535921A5 (enExample) | 2019-09-19 |
| JP6913077B2 JP6913077B2 (ja) | 2021-08-04 |
Family
ID=57984105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018507002A Active JP6913077B2 (ja) | 2015-08-13 | 2016-08-11 | タウの｛ｐ｝Ｓｅｒ４０４エピトープに対し選択的な、抗体を基にした分子、ならびにタウ異常症の診断および治療におけるそれらの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10358503B2 (enExample) |
| EP (1) | EP3334761B1 (enExample) |
| JP (1) | JP6913077B2 (enExample) |
| CN (1) | CN108137679B (enExample) |
| ES (1) | ES2954969T3 (enExample) |
| FI (1) | FI3334761T3 (enExample) |
| PT (1) | PT3334761T (enExample) |
| WO (1) | WO2017027691A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190134997A (ko) | 2017-02-17 | 2019-12-05 | 데날리 테라퓨틱스 인크. | 항-tau 항체 및 이의 사용 방법 |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| WO2019227490A1 (en) * | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
| WO2020123492A1 (en) * | 2018-12-10 | 2020-06-18 | New York University | Monoclonal antibodies targeting c-terminal region of phosphorylated tau |
| CN110028583B (zh) * | 2019-05-07 | 2020-09-11 | 温州医科大学 | 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用 |
| CA3137882A1 (en) * | 2019-05-23 | 2020-11-26 | Tamara SEREDENINA | Anti-tdp-43 binding molecules and uses thereof |
| US12281166B2 (en) | 2020-05-26 | 2025-04-22 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
| WO2024192429A1 (en) * | 2023-03-16 | 2024-09-19 | Abbvie Inc. | Assay for evaluating tau propagation |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| WO1991001754A1 (en) | 1989-08-09 | 1991-02-21 | Rhodes Buck A | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| JPH06508880A (ja) | 1991-07-08 | 1994-10-06 | ユニバーシティ オブ マサチューセッツ アット アムハースト | サーモトロピック液晶セグメント化ブロックコポリマー |
| ATE193301T1 (de) | 1993-03-09 | 2000-06-15 | Genzyme Corp | Verfahren zur isolierung von proteinen aus milch |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| MXPA01007895A (es) | 1999-02-03 | 2003-07-21 | Biosante Pharmaceuticals Inc | Particulas terapeuticas de fosfato de calcio, metodos de manufactura y usos. |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| HK1049014A1 (zh) | 1999-07-29 | 2003-04-25 | Medarex, Inc. | 抗her2/neu的人类单克隆抗体 |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| DK1354034T3 (da) | 2000-11-30 | 2008-03-25 | Medarex Inc | Transgene transchromosomale gnavere til fremstilling af humane antistoffer |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| EP4218794A3 (en) | 2009-06-10 | 2023-09-13 | New York University | Immunological targeting of pathological tau proteins |
| DK2625198T3 (en) | 2010-10-07 | 2015-09-28 | Ac Immune Sa | Antibodies that recognize the phosphorylated tau |
| JP6358953B2 (ja) * | 2011-10-07 | 2018-07-18 | エーシー イミューン エス．エー． | タウを認識するホスホ特異的抗体 |
| WO2014008404A1 (en) * | 2012-07-03 | 2014-01-09 | Washington University | Antibodies to tau |
| JP6290212B2 (ja) * | 2012-08-16 | 2018-03-07 | アイピエリアン，インコーポレイティド | タウオパチーの処置方法 |
| WO2014059442A2 (en) * | 2012-10-12 | 2014-04-17 | Arizona Board Agents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Antibody based reagents that specifically recognize toxic oligomeric forms of tau |
| US10132818B2 (en) | 2014-07-08 | 2018-11-20 | New York University | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| CN204439640U (zh) * | 2014-12-12 | 2015-07-01 | 北京海略世纪生物技术有限责任公司 | 一种新型筛查用老年痴呆速测试剂盒 |
-
2016
- 2016-08-11 FI FIEP16835899.2T patent/FI3334761T3/fi active
- 2016-08-11 US US15/750,982 patent/US10358503B2/en active Active
- 2016-08-11 JP JP2018507002A patent/JP6913077B2/ja active Active
- 2016-08-11 EP EP16835899.2A patent/EP3334761B1/en active Active
- 2016-08-11 CN CN201680057424.9A patent/CN108137679B/zh active Active
- 2016-08-11 PT PT168358992T patent/PT3334761T/pt unknown
- 2016-08-11 ES ES16835899T patent/ES2954969T3/es active Active
- 2016-08-11 WO PCT/US2016/046520 patent/WO2017027691A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018535921A5 (enExample) | ||
| JP2018534236A5 (enExample) | ||
| JP2017532288A5 (enExample) | ||
| JP2014502141A5 (enExample) | ||
| CA2832360C (en) | Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects | |
| Walker et al. | Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains | |
| IL225568A (en) | Phospho-specific antibodies for tau detection | |
| IL310464A (en) | Anti-phf-tau antibodies and uses thereof | |
| Ingram et al. | Complement activation in multiple sclerosis plaques: an immunohistochemical analysis | |
| JP2012530055A5 (enExample) | ||
| JP2015505665A5 (enExample) | ||
| JP6263473B2 (ja) | 脳における高レベルのα−シヌクレインを診断するための抗α−シヌクレイン抗体の使用 | |
| JP2017113004A5 (enExample) | ||
| FI3334761T3 (fi) | Vasta-ainepohjaisia molekyylejä, jotka ovat selektiivisiä Taun {p}Ser404-epitoopille, ja niiden käyttöjä tauopatian diagnosoinnissa ja hoidossa | |
| JP2014527398A5 (enExample) | ||
| JP2018511609A (ja) | 発作性夜間血色素尿症（ｐｎｈ）患者の亜集団の同定および処置 | |
| RU2016144178A (ru) | Антитело против muc1 или его антигенсвязывающий фрагмент и его применение | |
| JP2013542914A5 (enExample) | ||
| TW202243690A (zh) | 抗N3pGlu類澱粉β抗體及其用途 | |
| WO2017027685A3 (en) | Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy | |
| EP4028040A2 (en) | Biomarkers and treatments of alzheimer's disease and mild cognitive impairment | |
| CN116348769A (zh) | 用于检测tau蛋白病或淀粉样蛋白形成性疾病的基于血液的测定 | |
| JP2015522562A5 (enExample) | ||
| JP2014507649A (ja) | ヒト血液中の抗βアミロイド抗体の測定 | |
| Yoshihara et al. | Immunoreactivity of phage library-derived human single-chain antibodies to amyloid beta conformers in vitro |